<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="371821">
  <stage>Registered</stage>
  <submitdate>10/11/2016</submitdate>
  <approvaldate>14/07/2017</approvaldate>
  <actrnumber>ACTRN12617001021369</actrnumber>
  <trial_identification>
    <studytitle>Pentoxifylline versus progesterone medicated intrauterine device in controlling pain and increased menstrual blood  flow of women with adenomyosis</studytitle>
    <scientifictitle>Progesterone impregnated IUD versus pentoxifylline in management of women with symptomatic adenomyosis</scientifictitle>
    <utrn>U1111-1189-6654</utrn>
    <trialacronym>AMT (Adenomyosis management trial )</trialacronym>
    <secondaryid>none</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>dysmenorrhea</healthcondition>
    <healthcondition>chronic pelvic pain</healthcondition>
    <healthcondition>menorrhagia</healthcondition>
    <healthcondition>adenomyosis</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Other reproductive health and childbirth disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Levonorgestrel medicated intrauterine device  contain 52 mg of levonorgestrel , will be inserted by consultant ,as simple outpatient procedure . progestin provide a release rate of approximately 20mcg/day. It still reactive for five years, patient adherence checked one month then three months  after insertion and every one year visit. </interventions>
    <comparator>pentoxifylline oral tab(trental 200mg) twice daily for 3 months a phosphodiesterase inhibitor as angiogenesis inhibitors </comparator>
    <control>Active</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>dysmenorrhea pain measured by visual analogue score</outcome>
      <timepoint>baseline and 3 months post treatment commencement</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>chronic pelvic pain,measured by visual analogue score 
chronic pelvic pain means pain at lower abdominal pain last for six months or more.</outcome>
      <timepoint>baseline and 3 months post treatment commencement</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>menorrhagia,measured by hemoglobin deficit
hemoglobin deficit calculated by subtraction of baseline haemoglobin in grams from hemoglobin level  3 months post treatment commencement.</outcome>
      <timepoint> baseline and 3 months post treatment commencement</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>metrorrhagia 
its  uterine bleeding at irregular periods (yes or no catigorical variable)</outcome>
      <timepoint>baseline and 3 months post treatment commencement</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>numberof localized adenomyosis,measured by transvaginal ultrasound
 </outcome>
      <timepoint>baseline and 3 months post treatment commencement</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>uterine volume measured by transvaginal ultrasound
 measured in cubic cm </outcome>
      <timepoint>baseline and 3 months post treatment commencement</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome> volume of localized adenomyosis,measured by transvaginal ultrasound
volume measured in cubic cm </outcome>
      <timepoint>3 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Women with symptomatic adenomyosis (menstrual irregularities pain-subfertility):
1- Age more 30 years and less than 50.
2- Patients not seeking for fertility.
3- Patients were seeking an alternative to hysterectomy
</inclusivecriteria>
    <inclusiveminage>30</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>50</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1.	 Uterine fundal level  more than 20cm above symphysis pubis 
2.	Active pelvic infection or current use of  contraceptive
3.	Contraindication for medications 

</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>central randomisation by computer</concealment>
    <sequence>Simple randomisation using  coin-tossing</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>none</designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods>Sample size calculation done by statistician using G*Power 3.0.10      software assuming that type I alpha error 0.05 and type  Beta error 0.8 with confidence interval 80% and actual power 80% . 
35 patients will be randomly distributed in each  group.
</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>2/12/2017</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>70</samplesize>
    <actualsamplesize />
    <currentsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Egypt</country>
      <state>cairo</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>nahed allam</primarysponsorname>
    <primarysponsoraddress>AlAzhar university hospital
4Dawood barakat street
nasr city ,cairo
Egypt</primarysponsoraddress>
    <primarysponsorcountry>Egypt</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>alzahraa university hospital</fundingname>
      <fundingaddress>Elmostashfa elyounany street ,abassia
Cairo, Egypt 
postcode 11651</fundingaddress>
      <fundingcountry>Egypt</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Adenomyosis refers to a disorder in which  glands lining the womb cavity  present within the uterine musculature (uterine adenomyomatosis). The ectopic glandular tissue appears to induce thickening of the surrounding musculaure, which results in a diffusely enlarged womb.The medical treatment of adenomyosis is based on the hormonal dependency of the disease and its strongly share similarities with endometriosis,Two novel techniques will improve medical treatment over the next few years and even produce a preventive strategy: the first are new blood vessels  inhibitors and the second is the progesterone-releasing intrauterine device

</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Ethical and Research and approval by local ethical committee of OB/ Gyn department -AlAzhar university</ethicname>
      <ethicaddress>5 Alyonani hospital street 
Elabassia  ,cairo -Egypt </ethicaddress>
      <ethicapprovaldate>10/06/2016</ethicapprovaldate>
      <hrec>4863185</hrec>
      <ethicsubmitdate>4/05/2016</ethicsubmitdate>
      <ethiccountry>Egypt</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Nahed Ezzat Allam</name>
      <address>AlAzhar university hospital
4 Dawood Barakat street ,
nasr city,cairo
Egypt</address>
      <phone>+201229121089</phone>
      <fax />
      <email>nahedallam16@gmail.com</email>
      <country>Egypt</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Nahed Ezzat Allam</name>
      <address>AlAzhar university hospital
4 Dawood Barakat street ,
nasr city,cairo
Egypt</address>
      <phone>+201229121089</phone>
      <fax />
      <email>nahedallam16@gmail.com</email>
      <country>Egypt</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Taiseer Maarouf</name>
      <address>AlAzhar university hospital
street 9 ,Almokatum,cairo
Egypt</address>
      <phone>+201223660078</phone>
      <fax />
      <email>taiseer.maarouf@gmail.com</email>
      <country>Egypt</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Nahed Ezzat Allam</name>
      <address>4 dawood Barakat street ,nasr city.cairo,Egypt</address>
      <phone>+201229121089</phone>
      <fax />
      <email>nahedallam16@gmail.com</email>
      <country>Egypt</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>